Jowls, honestly.

No cream lifts, and the ones that say so are the subject of the "firming creams" row below. What a retinoid does is rebuild the upper dermis: in the randomised tretinoin trials, laxity was among the signs that improved alongside fine wrinkles and roughness, and the meta-analysis of those trials confirms the class effect (meta-analysis; overview). Daily sunscreen cut measured skin aging by 24% over 4.5 years in the one randomised prevention trial (Hughes 2013). Skin that is thicker, better hydrated and less sun-damaged drapes better over whatever is done underneath, heals better after devices and surgery, and shows the jowl less. Extend both to the jawline and neck, where most people stop. The wrinkles guide covers the retinoid ladder.

Nicotine constricts the dermal blood supply, smoke's oxidants destroy collagen and elastin, and pursing adds lip lines. Among 79 pairs of identical twins discordant for smoking, the smoker scored worse for jowls, nasolabial folds, upper-lip lines and lower-lid bags, and a five-year difference in smoking history was visible in photographs (twin study). Smoking also multiplies the risk of skin necrosis after a facelift, which is why surgeons demand weeks of abstinence. Nothing on this page beats not smoking for the price.

Weight cuts both ways. In a fuller face, a fat jowl shrinks with weight loss, and the jaw looks sharper. But fast loss — bariatric surgery, crash diets, and now GLP-1 injections — empties the deep fat compartments faster than the overlying skin can retract, and the result is folds, hollows and jowls that look a decade older; the 2025 reviews of GLP-1 facial changes describe exactly this, and a small imaging series shows facial fat volume falling on treatment (2025 review; imaging series). Weight cycling — the Guyuron twin series found the heavier twin looked older before 40 and younger after — adds laxity every time (Guyuron 2009).

Practically: lose slowly (half a kilo a week), keep protein high and lift weights so the loss is fat, and expect a deflated face to need volume rather than tightening afterward. Our 50s guide covers the GLP-1 trade-offs.

Oral collagen peptides improved skin elasticity and hydration in a 2018 meta-analysis of 11 randomised trials in 805 people (meta-analysis). Elasticity is the right property for a loose jowl, and the effect is real, but it is measured with a suction probe rather than seen in a mirror, and no trial has looked at the jawline. A reasonable, modest add-on; the collagen guide has the forms and doses.

A cream acts on the epidermis and, with retinoids, the upper dermis. A jowl is made two to three centimetres deeper, by fat, bone and a ligament. "Firming" products produce a sensation of tightness with film-forming polymers that contract as they dry, and "lifting" claims rest on instrument readings of skin hydration. The American Academy of Dermatology's own guidance for sagging skin is blunt: creams do not lift, and the options that do are procedures (AAD). The one cream that improves the skin's own laxity a little, over months, is a retinoid — see the first row.

In the 20-week pilot, 16 women who finished a daily facial-exercise programme were rated as having fuller upper and lower cheeks and looked about three years younger to blinded raters (Alam 2018). There was no control group, the jawline was not an outcome, and the plausible mechanism — hypertrophy of the cheek muscles — adds volume above the jowl rather than moving it. Harmless, free, and not a treatment for a fold.

Massage moves lymph and fluid, and for an hour or two the face is visibly less puffy: a randomised trial comparing a facial roller with gua sha found both reduced facial surface distances by about 2.2–2.4 mm, just above the threshold of a visible change (2025 trial). That is de-puffing, not lifting, and it is gone by the afternoon. Jaw-exerciser devices, sold for a "chiselled" jawline, produced no noticeable change in the two cases published, against a background of no supporting evidence at all (case report) — and building the masseter can widen the lower face in a way most women do not want.

Home radiofrequency devices deliver a fraction of the energy of their clinic cousins and the supporting studies are manufacturer-run and short (manufacturer study); microcurrent "toning" devices produce a brief muscle contraction and a brief puffiness reduction with no evidence of lasting change. Regulators cap consumer devices at energies that cannot burn, which also means they cannot heat the dermis to the temperature that contracts collagen. The clinic versions, graded below, are the honest ceiling of what the technology does.

Firm hyaluronic-acid gels placed along the mandibular border, into the prejowl hollow and onto the chin rebuild the edge the eye judges the jowl against. The evidence is a regulator-grade randomised trial: for Juvéderm Volux, 69.9% of treated patients were responders on the jawline-definition scale at six months against an untreated control group, and 82.3% reported satisfaction with their lower face and jawline through twelve months (FDA summary of safety and effectiveness; approval). MRI studies show hyaluronic gel persisting far longer than the folklore, which argues against routine top-ups (MRI review).

Read the endpoint carefully: "jawline definition", not "jowl removal". In a deflated face two to four syringes make a mild jowl vanish into a straight line; in a heavy face the same syringes add weight to a heavy jaw and make it worse. The pinch and profile tests decide. The filler guide covers gels, injectors and the reversal drug.

Calcium hydroxylapatite is a stiffer, mineral-based filler that provides immediate structure and stimulates collagen as its gel carrier is absorbed. Radiesse(+) was the first filler approved for improving jawline contour, on a 60-week prospective, randomised, controlled pivotal trial against an untreated group (pivotal trial), with long-term duration and safety data published in 2024 (Green 2024) and consensus guidance on placement (guidelines). Diluted, it doubles as a skin-quality treatment over the jowl and neck. Its limits are the same as Volux's — it frames, it does not remove — plus one more: it cannot be dissolved, so a first-time patient usually starts with hyaluronic acid.

Poly-L-lactic acid microspheres stimulate the patient's own collagen over months, restoring diffuse volume rather than drawing a line. Randomised trials in the lower face show correction that builds from month 3 and lasts up to 25 months (FDA summary; 2024 double-blind trial). For the post-weight-loss or postmenopausal face that has emptied everywhere, it re-inflates the cheek and prejowl gradually and naturally; for a defined jawline it is too soft, and for a heavy jowl it is wrong. Slow, subtle, irreversible, and dependent on the injector's dilution and massage to avoid nodules.

Deoxycholic acid destroys fat-cell membranes where it is injected, and the destroyed fat does not come back. Under the chin it is licensed across the EU on the strength of a phase-3 programme of about a thousand patients (pivotal programme; EU authorisation). In the jowl it is off-label, guided by cadaver studies of safe injection zones and clinical series rather than trials; a systematic review of serious adverse events emphasises that the marginal mandibular nerve runs exactly there, that temporary lip weakness follows careless placement, and that fat dissolution is contraindicated in the deflated jowl, where it deepens the hollow (systematic review; nerve weakness). For a genuinely fat jowl in a full face it is the one injectable that removes the pouch rather than framing it; expect a swollen fortnight after each session.

The platysma, the sheet muscle of the neck, inserts along the jaw and pulls the lower face down when it contracts. Injecting a row of toxin along the mandibular border and into the upper bands weakens that pull and lets the lifting muscles win by a few millimetres — the "Nefertiti lift" described in 2007, with recontouring reported in 97% of an uncontrolled series (Levy 2007; anatomical review). Toxin for platysmal bands themselves now has phase-3 trials and a 2024 approval (FDA approval), but the jawline-lift use has never been tested against placebo. It suits people whose jawline visibly worsens when they grimace, does nothing for fat or skin excess, and risks a weak smile or swallowing difficulty in the wrong hands.

Barbed absorbable threads are passed under the skin and pulled to hitch the jowl upward, on the promise of a "non-surgical facelift". In a randomised comparative trial of thread quantity, the initial improvement in volume and tissue position diminished by 60 days whatever the number of threads, and the authors could not find lasting lifting outcomes (randomised trial). A 2023 systematic review put the overall complication rate at 27% — skin dimpling 11%, bruising 8%, pain, extrusion and migration of the threads (systematic review), and a 2026 meta-analysis pools the complication data (meta-analysis). The collagen the dissolving threads leave behind is real and minor. For a loose jowl, the honest comparison is a few weeks of lift for a third of a facelift's price, repeated.

Platelet-rich plasma and its fibrin cousin deliver growth factors; polynucleotides are DNA fragments sold as "bioremodelling". Three randomised split-face trials show PRP modestly improving skin texture and fine lines, most clearly combined with microneedling (split-face trials); none measures lift, jawline position or jowl volume, because they do not move any of them. As a skin-quality add-on after a device or alongside a retinoid they are defensible; as a "PRP lift" they are a name. Our regenerative guide grades each product.